Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Net Cash Flow (2019 - 2025)

Addex Therapeutics' Net Cash Flow history spans 7 years, with the latest figure at $604.8 billion for Q2 2025.

  • On a quarterly basis, Net Cash Flow fell 73.05% to $604.8 billion in Q2 2025 year-over-year; TTM through Dec 2025 was $47.9 billion, a 100.87% increase, with the full-year FY2025 number at -$2.0 million, down 182.69% from a year prior.
  • Net Cash Flow came in at $604.8 billion for Q2 2025, up from -$556.9 billion in the prior quarter.
  • The five-year high for Net Cash Flow was $2313.4 billion in Q4 2023, with the low at -$6057.2 billion in Q3 2024.
  • Historically, Net Cash Flow has averaged -$302.5 billion across 5 years, with a median of -$2.2 million in 2021.
  • Peak annual rise in Net Cash Flow hit 68771161.25% in 2023, while the deepest fall reached 178495159.36% in 2023.
  • Year by year, Net Cash Flow stood at $5.6 million in 2021, then crashed by 159.79% to -$3.4 million in 2022, then skyrocketed by 68771161.25% to $2313.4 billion in 2023, then plummeted by 71.33% to $663.2 billion in 2024, then decreased by 8.8% to $604.8 billion in 2025.
  • Business Quant data shows Net Cash Flow for ADXN at $604.8 billion in Q2 2025, -$556.9 billion in Q1 2025, and $663.2 billion in Q4 2024.